<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0705245254
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZYPREXA 5MG COATED TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLANZAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        174.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Lilly S.A" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Lilly S.A
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 718]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ARAC HEALTHCARE
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ELI LILLY NEDERLAND B.V.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AH03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ZYPREXA contains the active substance olanzapine. ZYPREXA belongs to a group of medicines called antipsychotics and is used to treat the following conditions:</p><p>&middot;&nbsp;&nbsp; Schizophrenia, a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, and becoming withdrawn. People with this disease may also feel depressed, anxious or tense.</p><p>&middot;&nbsp;&nbsp; Moderate to severe manic episodes, a condition with symptoms of excitement or euphoria.</p><p>ZYPREXA has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take ZYPREXA</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to olanzapine or any of the other ingredients of this medicine (listed in section 6).<strong> </strong>An allergic reaction may be recognised as a rash, itching, a swollen face, swollen lips or shortness of breath. If this has happened to you, tell your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have been previously diagnosed with eye problems such as certain kinds of glaucoma (increased pressure in the eye)<strong>.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before you take ZYPREXA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The use of ZYPREXA in elderly patients with dementia is not recommended as it may have serious side effects.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines of this type may cause unusual movements mainly of the face or tongue. If this happens after you have been given ZYPREXA tell your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Very rarely, medicines of this type cause a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness. If this happens, contact your doctor at once.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weight gain has been seen in patients taking ZYPREXA. You and your doctor should check your weight regularly. Consider referral to a dietician or help with a diet plan if necessary.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking ZYPREXA. Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking ZYPREXA and regularly during treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell the doctor if you or someone else in your family has a history of blood clots, as medicines like these have been associated with the formation of blood clots.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As with other drugs that antagonize dopamine D receptors, olanzapine elevates prolactin levels, and the elevation persists during chronic administration. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactinelevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.</p><p>&nbsp;</p><p>If you suffer from any of the following illnesses tell your doctor as soon as possible:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stroke or &ldquo;mini&rdquo; stroke (temporary symptoms of stroke)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parkinson&rsquo;s disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prostate problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A blocked intestine (Paralytic ileus)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver or kidney disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you know that you may have salt depletion as a result of prolonged severe diarrhoea and vomiting (being sick) or usage of diuretics (water tablets)</p><p>&nbsp;</p><p>If you suffer from dementia, you or your carer/relative should tell your doctor if you have ever had a stroke or &ldquo;mini&rdquo; stroke.</p><p>&nbsp;</p><p>As a routine precaution, if you are over 65 years your blood pressure may be monitored by your doctor.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>ZYPREXA is not for patients who are under 18 years.</p><p>&nbsp;</p><p><strong>Other medicines and ZYPREXA</strong></p><p>Only take other medicines while you are on ZYPREXA if your doctor tells you that you can. You might feel drowsy if ZYPREXA is taken in combination with antidepressants or medicines taken for anxiety or to help you sleep (tranquillisers).</p><p>&nbsp;</p><p>&nbsp;</p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>In particular, tell your doctor if you are taking:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for Parkinson&rsquo;s disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your ZYPREXA dose.</p><p>&nbsp;</p><p><strong>ZYPREXA with alcohol</strong></p><p>Do not drink any alcohol if you have been given ZYPREXA as together with alcohol it may make you feel drowsy.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. You should not be given this medicine when breast-feeding, as small amounts of ZYPREXA can pass into breast milk.</p><p>&nbsp;</p><p>The following symptoms may occur in newborn babies, of mothers that have used ZYPREXA in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding. If your baby develops any of these symptoms you may need to contact your doctor.</p><p>Olanzapine is present in human milk. There are reports of excess sedation, irritability, poor feeding and extrapyramidal symptoms (tremors and abnormal muscle movements) in infants exposed to olanzapine through breast milk. There is no information on the effects of olanzapine on milk production.</p><p>The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for olanzapine and any potential adverse effects on the breastfed child from olanzapine or from the mother&rsquo;s underlying condition.</p><p>Infants exposed to olanzapine should be monitored for excess sedation, irritability, poor feeding, and extrapyramidal symptoms (tremors and abnormal muscle movements).</p><p>&nbsp;</p><p>Infertility</p><p>Females</p><p>Based on the pharmacologic action of olanzapine (D receptor antagonism), treatment with olanzapine may result in an increase in serum prolactin levels, which may lead to a reversible reduction in fertility in females of reproductive potential.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>There is a risk of feeling drowsy when you are given ZYPREXA. If this happens do not drive or operate any tools or machines. Tell your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>ZYPREXA contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Your doctor will tell you how many ZYPREXA tablets to take and how long you should continue to take them. The daily dose of ZYPREXA is between 5&nbsp;mg and 20 mg. Consult your doctor if your symptoms return but do not stop taking ZYPREXA unless your doctor tells you to.</p><p>You should take your ZYPREXA tablets once a day following the advice of your doctor. Try to take your tablets at the same time each day. It does not matter whether you take them with or without food. ZYPREXA coated tablets are for oral use. You should swallow the ZYPREXA tablets whole with water.</p><p><strong>If you take more ZYPREXA than you should</strong></p><p>Patients who have taken more ZYPREXA than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness. Other symptoms may be: acute confusion, seizures (epilepsy), coma, a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness, slowing of the breathing rate, aspiration, high blood pressure or low blood pressure, abnormal rhythms of the heart. Contact your doctor or hospital straight away if you experience any of the above symptoms. Show the doctor your pack of tablets.</p><p><strong>If you forget to take ZYPREXA</strong></p><p>Take your tablets as soon as you remember. Do not take two doses in one day.</p><p><strong>If you stop taking ZYPREXA</strong></p><p>Do not stop taking your tablets just because you feel better. It is important that you carry on taking ZYPREXA for as long as your doctor tells you.</p><p>If you suddenly stop taking ZYPREXA, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur. Your doctor may suggest you to reduce the dose gradually before stopping treatment.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Tell your doctor immediately if you have:</p><p>&middot;&nbsp;&nbsp; unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue;</p><p>&middot;&nbsp;&nbsp; blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. If you notice any of these symptoms seek medical advice immediately;</p><p>&middot;&nbsp;&nbsp; a combination of fever, faster breathing, sweating, muscle stiffness and drowsiness or sleepiness (the frequency of this side effect cannot be estimated from the available data).</p><p>Very common side effects (may affect more than 1 in 10 people) include weight gain; sleepiness; and increases in levels of prolactin in the blood. In the early stages of treatment, some people may feel dizzy or faint (with a slow heart rate), especially when getting up from a lying or sitting position. This will usually pass on its own but if it does not, tell your doctor.</p><p>Common side effects (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements(dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males.</p><p>Uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching, rash); diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; &nbsp;problems with speech; stuttering; slow heart rate; sensitivity to sunlight; bleeding from the nose; abdominal distension; drooling; memory loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss; absence or decrease in menstrual periods; and changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth.</p><p>Rare side effects (may affect up to 1 in 1000 people) include lowering of normal body temperature; abnormal rhythms of the heart; sudden unexplained death; inflammation of the pancreas causing severe stomach pain, fever and sickness; liver disease appearing as yellowing of the skin and white parts of the eyes; muscle disease presenting as unexplained aches and pains; and prolonged and/or painful erection.</p><p>Very rare side effects include serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).&nbsp; DRESS appears initially as flu-like symptoms with a rash on the face and then with an extended rash, high temperature, enlarged lymph nodes, increased levels of liver enzymes seen on blood tests and an increase in a type of white blood cells (eosinophilia).</p><p>While taking olanzapine, elderly patients with dementia may suffer from stroke, pneumonia, urinary incontinence, falls, extreme tiredness, visual hallucinations, a rise in body temperature, redness of the skin and have trouble walking. Some fatal cases have been reported in this particular group of patients.</p><p>In patients with Parkinson&#39;s disease ZYPREXA may worsen the symptoms.</p><p>Additional information on special populations</p><p>Olanzapine administered with lithium or valproate was associated with increased levels (olanzapine combination vs. placebo) of tremor (23% vs 13%), dry mouth (32% vs 9%), increased appetite (24% vs 8%), increased salivation (6% vs 2%) , weight gain (26% vs 7%), dizziness (14% vs 7%), back pain (8% vs 4%), constipation (8% vs 4%). Speech disorder&nbsp; (7% vs 1%) was also reported commonly, amnesia (5% vs 2%), and paresthesia (5% vs 2%).</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in section 6. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of sight and reach of children.</p><p>Do not use this medicine after the expiry date, which is stated on the carton<strong>.</strong></p><p>ZYPREXA should be stored in its original pack in order to protect from light and moisture. Store below 30 &deg;C.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What ZYPREXA contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is olanzapine. Each ZYPREXA tablet contains 5 mg or 10 mg of the active substance. The exact amount is shown on your ZYPREXA tablet pack.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (tablet core) lactose monohydrate, hyprolose, crospovidone, microcrystalline cellulose, magnesium stearate and</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (tablet coating) hypromellose, titanium dioxide (E171), carnauba wax.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In addition the different ZYPREXA tablet strengths also contain the following ingredients:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>TABLET STRENGTH </strong></p></td><td style="vertical-align:top"><p><strong>OTHER INGREDIENTS</strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>ZYPREXA 5 mg and 10 mg tablets</p></td><td style="vertical-align:top"><p>(tablet coating) shellac, macrogol, propylene glycol, polysorbate 80 and indigo carmine colour (E132), ethanol anhydrous, isopropyl alcohol, butyl alcohol, ammonium hydroxide</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ZYPREXA 5 mg coated tablets are white imprinted with “LILLY” and a numeric identicode “4115”. 
ZYPREXA 10 mg coated tablets are white imprinted with “LILLY” and a numeric identicode “4117”.

ZYPREXA is available in packs containing 28, 35, 56, 70 or 98 tablets. Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder </strong></p><p>Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.</p><p><strong>Manufacturer </strong></p><p>Lilly S.A., Avda. de la Industria 30, 28108 Alcobendas, Madrid, Spain</p><p>Lilly del Caribe, Inc., Puerto Rico Industrial Park, 12.6Km 65th Infantry Road. Carolina, Puerto Rico 00985.</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Eli Lilly &amp; Company &ndash; Saudi Arabia</p><p>PO Box 92120</p><p>16th Floor, Building Number 3074,</p><p>Tower B, Olaya Towers</p><p>Prince Mohamed Ibn Abdulaziz Street</p><p>Olaya, Riyadh</p><p>Kingdom of Saudi Arabia</p><p>Direct Line:&nbsp; +966 11 461 7800, +966 11 4617850&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Fax: +966 11 217 9900</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in February 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي زيبريكسا على المادة الفعالة أولانزابين. ينتمي زيبريكسا &nbsp;إلى مجموعة من الأدوية تُسمّى مضادات الذهان وهو يُستعمل لعلاج الحالات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انفصام الشخصيّة، وهو مرض &nbsp;يسببّب أعراضًا مثل سماع أشياء غير موجودة أو رؤيتها أو الإحساس بها ، ومعتقدات خاطئة، وشكوك غير معتادة، والانطواء على الذات. قد يشعر المصابون بهذا المرض كذلك بالاكتئاب أو القلق أو التوتر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات الهوس المتوسطة إلى الشديدة، وهي حالة تسبّب أعراض الإثارة أو النشوة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تبيّن أن زيبريكسا يمنع تكرار هذه الأعراض لدى المرضى المصابين بالإضطراب ثنائي القطب الذين استجابت نوباتالهوس لديهم للعلاج باستخدام الأولانزابين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول زيبريكسا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية (فرط الحساسية) تجاه الأولانزابين أو أيّ من المكوّنات الأخرى لهذا الدواء (المفصلة في القسم 6). يمكن التعرّف على رد الفعل التحسسي من خلال الطفح الجلدي، والحكّة، وتورّم الوجه، وتورّم الشفتين أو ضيق التنفس. إذا حدث لك ذلك، أبلغ طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تمّ تشخيص إصابتك في السابق &nbsp;بمشاكل في العين مثل بعض أنواع الزرق (زيادة الضغط داخل العين).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل أن تتناول زيبريكسا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يوصى باستخدام زيبريكسا في المرضى المسنين المصابين بالخرف، لأنّ ذلك قد يؤدي إلى آثار جانبية خطيرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تسبب أدوية من هذا النوع حركات غير عاديّة، &nbsp;بخاصة في الوجه أو اللسان. إذا حدث ذلك بعد إعطائك زيبريكسا، أبلغ طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالات نادرة للغاية، تسبب أدوية من هذا النوع مزيجًا من الحمى، وتسارع التنفس، والتعرّق، والتصلّب العضلي، والدوخة أوالنعاس. في حالة حدوث ذلك، اتصل بطبيبك فورًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوحظت زيادة الوزن في المرضى الذين يتناولون زيبريكسا. عليك أنت وطبيبك قياس وزنك بانتظام. فكّر في الذهاب إلى اختصاصي للتغذية أو في الحصول على المساعدة &nbsp;لاتباع حمية غذائيّة عند الضرورة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوحظ ارتفاع مستوى السكر في الدم وارتفاع مستويات الدهون (الدهون الثلاثية والكولسترول) في المرضى الذين يتناولون زيبريكسا. ينبغي لطبيبك القيام باختبارات للدم لفحص مستوى السكر في الدم والتأكّد من مستويات بعض أنواع الدهون قبل أن تبدأ بتناول زيبريكسا وعلى فترات منتظمة أثناء العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أبلغ طبيبك في حال سبق لك أو لأيّ من أفراد عائلتك الإصابة بخثرات دمويّة، حيث صاحب استخدام مثل هذه الأدوية تكوّن خثرات دموية.</p><p dir="RTL">كما هو الحال مع الأدوية الأخرى المضادة لمستقبلات الدوبامين د، فإن الأولانزابين يرفع مستويات البرولاكتين، ويستمرّ هذا الارتفاع خلال الاستعمال المزمن للدواء . قد يثبّط فرط البرولاكتين في الدم هرمون (GnRH) &nbsp;&nbsp;الوطائي، مما يؤدي إلى انخفاض إفراز الغدة النخامية لموجّهة الغدد التناسلية. وقد يثبط هذا بدوره، الوظيفة الإنجابية عن طريق إعاقة تكوين الستيرويد التناسلي لدى كلّ من المرضى من الإناث والذكور. تم الإبلاغ عن ثرّ اللبن، وانقطاع الطمث، والتثدي، والعجز الجنسي لدى المرضى الذين يتلقون مركّبات رفع مستوى البرولاكتين. قد يؤدي فرط برولاكتين الدم طويل الأمد عندما يرتبط بقصور الغدد التناسلية إلى انخفاض كثافة العظام لدى كل من الإناث والذكور.</p><p dir="RTL">إذا كنت تعاني من أيّ من الأمراض التالية، أبلغ طبيبك في أقرب فرصة ممكنة:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السكتة الدماغية أو السكتة الدماغية &quot; الصغيرة&quot; (أعراض مؤقتة للسكتة الدماغية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء باركنسون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في البروستات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انسداد الأمعاء (العلوص الشللي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض الكبد أو الكلى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات &nbsp;الصرع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعرف أنك قد تكون مصاباً بنقص الأملاح بسبب الإسهال أو القيء الشديد الممتد لفترات طويلة أو استخدام مدرّات البول (أقراص الماء).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من الخرف، فينبغي عليك أو &nbsp;على المسؤول عن رعايتك/ قريبك إبلاغ الطبيب إذا سبق تعرّضك لسكتة دماغية أو سكتة دماغية &quot; صغيرة&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">كإجراء احترازي روتيني، إذا كان عمرك يزيد عن 65 عامًا، فقد يقوم طبيبك بمراقبة ضغط الدم لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">زيبريكسا غير مخصص للاستعمال في المرضى الذين يقلّ عمرهم عن 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وزيبريكسا</strong></p><p dir="RTL">لا تتناول أيّ أدوية أخرى أثناء علاجك بزيبريكسا إلا إذا قال لك طبيبك إن باستطاعتك ذلك. قد تشعر &nbsp;بالنعاس عند تناول زيبريكسا مع مضادات الاكتئاب أو الأدوية المستخدمة لعلاج القلق أو للمساعدة في النوم (المهدّئات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ طبيبك إذا كنت تتناول حاليًا&nbsp; أو تناولت مؤخّرًا أو قد تكون تتناول أيّ أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحديدًا، أبلغ طبيبك إذا كنت تتناول:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج داء باركنسون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربامازيبين (مضاد للصرع ومثبت للمزاج) أو فلوفوكسامين (مضاد للاكتئاب) أو سيبروفلوكزاسين (مضاد حيوي) &ndash; قد يكون من الضروري تغيير جرعتك من زيبريكسا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>زيبريكسا مع الكحول</strong></p><p dir="RTL">لا تشرب الكحول إذا أعطيت زيبريكسا، &nbsp;لأنّ &nbsp;استخدامه مع الكحول قد &nbsp;يجعلك تشعر بالنعاس.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعة أو &nbsp;تعتقدين نفسك حاملاً أو تخططين للإنجاب، استشيري طبيبك قبل تناول هذا الدواء. لا &nbsp;ينبغي إعطاؤك هذا الدواء أثناء فترة الرضاعة، لأنّ كميّات صغيرة من زيبريكسا يمكن أن تنتقل إلى حليب الأم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن حدوث الأعراض التالية في الأطفال حديثي الولادة أو الأمهات &nbsp;اللواتي تناولنَ عقار زيبريكسا خلال الثلث الأخير من الحمل (الأشهر الثلاثة الأخيرة من حملهنّ): الرعشة، التصلب و/أو الضعف العضلي ، النعاس، الهياج، مشاكل التنفس، وصعوبة التغذية. إذا أصيب &nbsp;طفلك بأيّ من هذه الأعراض، فقد تحتاجين للاتصال بطبيبك.</p><p dir="RTL">الأولانزابين موجود&nbsp; في حليب الأم. &nbsp;أفيد عن حالات من فرط التخدير والتهيّج وسوء التغذية وأعراض خارج الهرميّة (رعاش وحركات عضلية غير طبيعية) عند الرّضع المعرّضين لأولانزابين من خلال حليب الثدي. لا توجد معلومات عن تأثيرات الأولانزابين على إنتاج الحليب.</p><p dir="RTL">يجب &nbsp;الأخذ بالاعتبار الفوائد &nbsp;المتعلّقة بالنموّ والصحّة للرضاعة الطبيعية جنبًا إلى جنب مع الحاجة السريرية للأولانزابين لدى الأم وأي آثار جانبية محتملة على الطفل الرضيع من جراء استعمال الأولانزابين أو من الحالة الأساسيّة للأم.</p><p dir="RTL">يجب مراقبة الأطفال الرضّع المعرضين للأولانزابين لخطر التخدير الزائد والتهيّج وسوء التغذية والأعراض خارج الهرميّة (الرعشة وحركات العضلات غير الطبيعية).</p><p dir="RTL">&nbsp;</p><p>العقم</p><p>الإناث</p><p dir="RTL">بناءً على التأثير الدوائي للأولانزابين (مضادات مستقبلات د)، قد يؤدي العلاج بالأولانزابين إلى زيادة مستويات البرولاكتين في الدم ، مما قد يؤدي إلى انخفاض في الخصوبة قابل للزوال عند الإناث القادرات على الإنجاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;قد تشعر بالنعاس عند إعطائك زيبريكسا. إذا حدث ذلك ، لا تقد السيّارة ولا تشغّل أيّ أدوات أو آلات وأبلغ طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي زيبريكسا على اللاكتوز</strong></p><p dir="RTL">إذا &nbsp;أعلمك طبيبك أنك مصاب بعدم تحمّل بعض السكريات، فاتصل به قبل استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول &nbsp;هذا الدواء دائمًا كما قال لك طبيبك تمامًا. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيُعلمك طبيبك بكمية أقراص زيبريكسا التي يجب عليك تناولها ومدة &nbsp;تناولك لها. تتراوح الجرعة اليومية من زيبريكسا بين 5 ملجم و20 ملجم. استشر طبيبك إذا عادت أعراضك ولكن لا توقف تناول زيبريكسا حتى &nbsp;يطلب طبيبك منك ذلك.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">عليك تناول أقراص زيبريكسا مرّة يوميًا مع اتباع نصيحة طبيبك. حاول تناول أقراصك في الوقت ذاته من كل يوم. يمكنك أن تتناولها مع الطعام أو بدونه. يتمّ تناول أقراص زيبريكسا عن طريق الفم. عليك بلع أقراص زيبريكسا كاملة مع الماء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت كمية أكثر مما ينبغي من زيبريكسا</strong></p><p dir="RTL">تعرّض المرضى ممن تناولوا كمية أكثر مما ينبغي من زيبريكسا للأعراض التالية: ضريات القلب السريعة، الهياج/ العدائية، مشاكل النطق، الحركات غير المعتادة (خاصةً في الوجه أو اللسان) ونقص مستوى الوعي. قد تتضمن باقي الأعراض: الارتباك الحاد، النوبات التشنجية (الصرع)، الغيبوبة، مزيج من الحمى وتسارع التنفس، والتعرق، والتصلب العضلي، والنعاس أو النوام، وتباطؤ معدل التنفس، والاستنشاق، وارتفاع أو انخفاض ضغط الدم، واضطراب نظم القلب. اتصل بطبيبك أو المستشفى حالًا في حالة إصابتك بأيّ من هذه الأعراض. اعرض عبوة الأقراص على طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول زيبريكسا</strong></p><p dir="RTL">تناول الأقراص حالما تتذكّر. لا تتناول جرعتين في اليوم نفسه.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا أوقفت تناول زيبريكسا</strong></p><p dir="RTL">لا توقف تناول أقراصك عند شعورك بالتحسن. من المهم أن تستمر في تناول زيبريكسا للمدة التي &nbsp;يحددها طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أوقفت تناول زيبريكسا فجأةً، فيمكن أن تحدث أعراض كالتعرّق، وعدم القدرة على النوم، والرعشة، والقلق أو الغثيان والقيء. قد يقترح عليك طبيبك &nbsp;تخفيض الجرعة &nbsp;تدريجيًا قبل إيقاف العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك المزيد من الأسئلة &nbsp;حول استعمال هذا الدواء، استشر طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ككل الأدوية، يمكن أن يسبّب هذا الدواء آثارًا &nbsp;جانبية، رغم أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبلغ طبيبك فورًا في حالة إصابتك بما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات غير عاديّة (أثر جانبي شائع قد يصيب ما يصل 1 من كل 10 أشخاص) وخاصًة في الوجه أو اللسان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خثرات دموية في الأوردة (أثر جانبي غير شائع قد يصيب ما يصل 1 من كل 100 شخص) خاصة في الساقين (تتضمن الأعراض التورّم والألم واحمرار الساق)، ويمكن لهذه الخثرات أن تنتقل من خلال الأوعية الدموية لتصل إلى الرئتين وتسبب ألمًا بالصدر وصعوبة في التنفس. إذا لاحظت أيًا من هذه الأعراض، استشر الطبيب فورًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مزيج من الحمى وتسارع التنفّس، والتعرّق، والتصلّب العضلي، والنعاس أو النوام (ليس من الممكن تقدير معدل حصول الأثر الجانبي هذا من البيانات المتاحة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن الآثار الجانبية بالغة الشيوع (قد تصيب أكثر من 1 من كل 10 أشخاص) زيادة الوزن، والنوام، وزيادة مستويات البرولاكتين في الدم. في المراحل المبكرة من العلاج، قد يشعر بعض الأشخاص بالدوار أو الإغماء (مع تباطؤ نبض القلب)، وخاصة عند النهوض من وضع الاستلقاء أو من وضع الجلوس. عادة ما ينتهي ذلك تلقائيًا، ولكن في حال عدم حصول ذلك أبلغ طبيبك.</p><p dir="RTL">تتضمن الآثار الجانبية الشائعة (قد تصيب ما يصل 1 من كل 10 أشخاص) تغيّرات في مستويات خلايا الدم، والدهون الموجودة في الدورة الدموية، وتتضمن في وقت مبكر من العلاج زيادات مؤقتة في إنزيمات الكبد، وزيادة مستوى السكريات في الدم والبول، وزيادة مستويات حمض اليوريك &nbsp;و فوسفوكيناز الكرياتين في الدم، والشعور بمزيد من الجوع، والدوار، والتململ، والرعشة، والحركات غير العادية (خلل الحركة)، والإمساك، وجفاف الفم، والطفح الجلدي، وضعف القوة، والإرهاق الفائق، واحتباس الماء مما يؤدي &nbsp;إلى تورم اليدين والكاحلين أو القدمين، والحمى، وألم المفاصل، والاختلالات الجنسية مثل ضعف الشهوة الجنسية في الإناث والذكور أو ضعف الانتصاب في الذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن الآثار الجانبية غير الشائعة (قد تصيب ما يصل 1 من كل 100 شخص) فرط الحساسية (مثل تورم الفم أو الحلق، والحكة، والطفح الجلدي)، داء السكري أو تدهور داء السكري، وأحيانًا الحماض الكيتوني المصاحب (وجود الكيتونات في الدم أو البول) أو الغيبوبة، النوبات التشنجية، وعادة ما يرتبط ذلك بتاريخ من النوبات التشنجية (الصرع)، تصلّب العضلات أو تشنّجها &nbsp;(ويشمل ذلك حركات العين)، متلازمة تململ الساقين، مشاكل في النطق، تأتأة، &nbsp;بطء معدّل ضربات القلب، الحساسية من ضوء الشمس، النزف من الأنف، انتفاخ البطن، سيلان اللعاب، ضعف الذاكرة أو القابليّة للنسيان، السلس البولي، ضعف القدرة على التبول، تساقط الشعر، غياب أو نقص الدورات الشهرية، وتغيرات الثديين في الذكور والإناث مثل الإنتاج غير الطبيعي لحليب الثدي أو النمو غير الطبيعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">تتضمن الآثار الجانبية النادرة (قد تصيب ما يصل 1 من كل 1000 شخص) نقص درجة الحرارة الطبيعية للجسم، والنظم غير الطبيعي للقلب، والوفاة المفاجئة غير المبررة، والتهاب البنكرياس الذي يسبب ألمًا شديدًا بالبطن، والحمى والإعياء، ومرض الكبد في صورة اصفرار الجلد والأجزاء البيضاء من العينين، والمرض العضلي في صورة أوجاع غير مبررة، والانتصاب المطول و/أو المؤلم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشمل الآثار &nbsp;الجانبية النادرة جداً ردود فعل تحسسية مثل &nbsp;التفاعل الدوائي مع فرط في الحمضات وأعراض جهازية.&nbsp; يظهر التفاعل الدوائي هذا مبدئياً في شكل أعراض الأنفلونزا مع طفح على &nbsp;الوجه، ثم يمتد الطفح وترتفع درجة الحرارة ويحدث تضخّم العقد الليمفاوية، وزيادة مستويات إنزيمات الكبد في اختبارات الدم، وزيادة في نوع من خلايا الدم البيضاء ( فرط الحمضات).</p><p dir="RTL">أثناء تناول الأولانزابين، فإن المرضى المسنين المصابين بالخرف قد يعانون من السكتة الدماغية، والالتهاب الرئوي، والسلس البولي، والسقطات، والإرهاق الفائق، والهلوسات البصرية، وارتفاع درجة حرارة الجسم، واحمرار الجلد، وصعوبة المشي. &nbsp;وقد أفيد عن بعض حالات الوفاة لدى هذه المجموعة المحددة من المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في مرضى داء باركنسون، قد يزيد زيبريكسا أعراض سوءًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>م</u><u>ع</u><u>لومات إضافيّة حول فئات خاصة من الناس</u></p><p dir="RTL">ارتبط استعمال الأولازبين مع الليثيوم أو الفالبروات (تركيبة أولازبين مقابل الدواء الوهمي) بزيادة مستويات الارتعاش (23% مقابل 13%)، جفاف الفم (32% مقابل 9%)، زيادة الشهية (24% مقابل 8%)، زيادة إفراز اللعاب (6% مقابل 2%)، زيادة الوزن (26% مقابل 7%)، &nbsp;الدوار (14% مقابل 7%)، آلام الظهر (8% مقابل 4%)، الإمساك (8% مقابل 4%). تم الإبلاغ أيضًا عن اضطراب في الكلام (7% مقابل 1%) بشكل شائع، وفقدان الذاكرة (5% مقابل 2%)، وتشوّش الحس (5% مقابل 2%).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">في حالة إصابتك بأيّ آثار جانبية، أبلغ طبيبك أو الممرضة. يتضمن ذلك أيّ آثار جانبية محتملة غير مذكورة في هذه النشرة.</p><p dir="RTL">يمكنك أيضًا الإبلاغ عن أيّ آثار جانبية بشكل مباشر عن طريق النظام الوطني للإبلاغ عن الآثار الجانبية المذكور في القسم 6. إن إبلاغك عن الآثار الجانبية يساعد في توفير معلومات إضافية عن سلامة هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيدًا عن متناول الأطفال ونظرهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على علبة &nbsp;الكرتون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب تخزين زيبريكسا في عبوته الأصلية لحمايته من الضوء والرطوبة. يحفظ في درجة حرارة أقلّ من &nbsp;30 درجة مئوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلّص من أيّ أدوية من خلال الصرف الصحي أو النفايات المنزلية. استشر الصيدلي بخصوص كيفية التخلص من أيّ أدوية لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات زيبريكسا</strong></p><p>&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة &nbsp;الفعالة هي الأولانزابين. يحتوي كل قرص من زيبريكسا على 5 ملجم أو 10 ملجم من المادة الفعالة. الكمية الدقيقة مذكورة على عبوة أقراص زيبريكسا الخاصة بك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكوّنات الأخرى هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (لبّ القرص) لاكتوز أحادي الهيدرات، هيبرولوز، كروسبوفيدون، السليلولوز الغروي الدقيق، ستيريت الماغنسيوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (غلاف القرص) هيبروميللوز، ثاني أكسيد التيتانيوم (إي 171)، وشمع الكارنوبا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالإضافة لذلك، فإن أقراص زيبريكسا ذات التركيزات المختلفة تحتوي كذلك على المكوّنات التالية:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>تركيز القرص</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>المكونات الأخرى</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">أقراص زيبريكسا 5 ملجم و 10 ملجم</p></td><td style="vertical-align:top"><p dir="RTL">(غلاف القرص) صمغ اللك، ماكروجول، بروبيلين جلايكول، بوليسوربات 80، الصبغة القرمزية النيلية (إي 132)، الإيثانول اللامائي، كحول الأيزوبروبايل، كحول البيوتايل، هيدروكسيد الأمونيا</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>شكل زيبريكسا ومحتويات العبوة</strong></p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">أٌقراص زيبريكسا 5 ملجم المغلّفة تكون بيضاء اللون مطبوع على أحد جانبيّ القرص كلمة &quot;LILLY&quot; وعلى الجانب الآخر رمز تعريف رقمي &nbsp;&quot;4115&quot;</p><p dir="RTL" style="text-align:right">أٌقراص زيبريكسا 10 ملجم المغلّفة تكون بيضاء اللون مطبوع على أحد جانبيّ القرص كلمة &quot;LILLY&quot; وعلى الجانب الآخر رمز تعريف رقمي 4117&quot;&quot;.</p><p dir="RTL" style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right">تتوفر أقراص زيبريكسا في عبوات تحتوي على 28 قرصاً أو 35 قرصاً أو 56 قرصًا أو 70 قرصاً أو 98 قرصًا. قد لا يتمّ تسويق العبوات بكل الأحجام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل رخصة التسويق</strong></p><p dir="RTL">إيلي ليلي هولندا &nbsp;B.V.بابندوربسوغ 83، 3528، &nbsp;BJأوترخت،&nbsp; هولندا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المُصنّع</strong></p><p dir="RTL">ليلي س.أ. اندستريا 30، 28108 ألكوبنداس )مدريد(، إسبانيا.</p><p dir="RTL">لیلي دل كریبي، INC بویرتو ریكو، المنطقة الصناعیة، 12.6 كلم .65<sup>th</sup> طریق إنفنتري. كرولینا، بویرتو ریكو .00985</p><p dir="RTL">&nbsp;</p><p dir="RTL">للحصول على معلومات عن هذا الدواء، يُرجى الاتصال بالممثّل المحلّي للشركة حاملة رخصة التسويق:</p><p dir="RTL">شركة إيلي ليلي آند كومباني- المملكة العربية السعودية</p><p dir="RTL">ص.ب: 92120</p><p dir="RTL">الطابق 16، مبنى رقم 3074،</p><p dir="RTL">برج ب، أبراج العُليَّا</p><p dir="RTL">شارع الأمير محمد بن عبد العزيز</p><p dir="RTL">العُليَّا، الرياض</p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">الخط المباشر: 966114617800+, +966114617850</p><p dir="RTL">الفاكس: 966112179900+</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            جرت مراجعة هذه النشرة في فبراير 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZYPREXA 5 mg coated tablets
ZYPREXA 10 mg coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZYPREXA 5 mg coated tablets
Each coated tablet contains 5 mg olanzapine. 

Excipient with known effect: Each coated tablet contains 156 mg lactose monohydrate.

ZYPREXA 10 mg coated tablets

Each coated tablet contains 10 mg olanzapine. 
Excipient with known effect: Each coated tablet contains 312 mg lactose monohydrate.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Coated tablet

ZYPREXA 5 mg coated tablets
Round, white, coated tablets imprinted with “LILLY” and a numeric identicode “4115”.

ZYPREXA 10 mg coated tablets
Round, white, coated tablets imprinted with “LILLY” and a numeric identicode “4117”.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adults</u></p><p>Olanzapine is indicated for the treatment of schizophrenia.</p><p>&nbsp;</p><p>Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.</p><p>&nbsp;</p><p>Olanzapine is indicated for the treatment of moderate to severe manic episode.</p><p>&nbsp;</p><p>In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adults</u></p><p>Schizophrenia: The recommended starting dose for olanzapine is 10&nbsp;mg/day.</p><p>&nbsp;</p><p>Manic episode: The starting dose is 15&nbsp;mg as a single daily dose in monotherapy or 10&nbsp;mg daily in combination therapy (see section 5.1).</p><p>&nbsp;</p><p>Preventing recurrence in bipolar disorder: The recommended starting dose is 10&nbsp;mg/day. For patients who have been receiving olanzapine for treatment of manic episode, continue therapy for preventing recurrence at the same dose. If a new manic, mixed, or depressive episode occurs, olanzapine treatment should be continued (with dose optimisation as needed), with supplementary therapy to treat mood symptoms, as clinically indicated.</p><p>&nbsp;</p><p>During treatment for schizophrenia, manic episode and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5-20&nbsp;mg/day. An increase to a dose greater than the recommended starting dose is advised only after appropriate clinical reassessment and should generally occur at intervals of not less than 24 hours. Olanzapine can be given without regards for meals as absorption is not affected by food. Gradual tapering of the dose should be considered when discontinuing olanzapine.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>A lower starting dose (5&nbsp;mg/day) is not routinely indicated but should be considered for those 65 and over when clinical factors warrant (see section 4.4).</p><p><strong>&nbsp;</strong></p><p><em>Renal and/or hepatic impairment</em></p><p>A lower starting dose (5&nbsp;mg) should be considered for such patients. In cases of moderate hepatic insufficiency (cirrhosis, Child-Pugh Class A or B), the starting dose should be 5&nbsp;mg and only increased with caution.</p><p>&nbsp;</p><p><em>Smokers</em></p><p>The starting dose and dose<em> </em>range need not be routinely altered for non-smokers relative to smokers. The metabolism of olanzapine may be induced by smoking. Clinical monitoring is recommended and an increase of olanzapine dose may be considered if necessary (see section 4.5).</p><p>&nbsp;</p><p>When more than one factor is present which might result in slower metabolism (female gender, geriatric age, non-smoking status), consideration should be given to decreasing the starting dose. Dose escalation, when indicated, should be conservative in such patients.</p><p>&nbsp;</p><p>(See sections 4.5 and 5.2)</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Olanzapine is not recommended for use in children and adolescents below 18&nbsp;years of age due to a lack of data on safety and efficacy. A greater magnitude of weight gain, lipid and prolactin alterations has been reported in short term studies of adolescent patients than in studies of adult patients (see sections 4.4, 4.8, 5.1 and 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.  
Patients with known risk of narrow-angle glaucoma.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During antipsychotic treatment, improvement in the patient&#39;s clinical condition may take several days to some weeks. Patients should be closely monitored during this period.</p><p>&nbsp;</p><p><u>Dementia-related psychosis and/or behavioural disturbances</u></p><p>Olanzapine is not recommended for use in patients with dementia-related psychosis and/or behavioural disturbances because of an increase in mortality and the risk of cerebrovascular accident. In placebo-controlled clinical trials (6-12 weeks duration) of elderly patients (mean age 78 years) with dementia-related psychosis and/or disturbed behaviours, there was a 2-fold increase in the incidence of death in olanzapine‑treated patients compared to patients treated with placebo (3.5% vs. 1.5%, respectively). The higher incidence of death was not associated with olanzapine dose (mean daily dose 4.4&nbsp;mg) or duration of treatment. Risk factors that may predispose this patient population to increased mortality include age &gt;&nbsp;65 years, dysphagia, sedation, malnutrition and dehydration, pulmonary conditions (e.g., pneumonia, with or without aspiration), or concomitant use of benzodiazepines. However, the incidence of death was higher in olanzapine-treated than in placebo-treated patients independent of these risk factors.</p><p>&nbsp;</p><p>In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischemic attack), including fatalities, were reported. There was a 3-fold increase in CVAE in patients treated with olanzapine compared to patients treated with placebo (1.3% vs. 0.4%, respectively). All olanzapine- and placebo-treated patients who experienced a cerebrovascular event had pre-existing risk factors. Age &gt;&nbsp;75 years and vascular/mixed type dementia were identified as risk factors for CVAE in association with olanzapine treatment. The efficacy of olanzapine was not established in these trials.</p><p><em>&nbsp;</em></p><p><u>Parkinson&#39;s disease</u></p><p>The use of olanzapine in the treatment of dopamine agonist associated psychosis in patients with Parkinson&#39;s disease is not recommended. In clinical trials, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo (see section 4.8), and olanzapine was not more effective than placebo in the treatment of psychotic symptoms. In these trials, patients were initially required to be stable on the lowest effective dose of anti-Parkinsonian medicinal products (dopamine agonist) and to remain on the same anti-Parkinsonian medicinal products and dosages throughout the study. Olanzapine was started at 2.5&nbsp;mg/day and titrated to a maximum of 15&nbsp;mg/day based on investigator judgement.</p><p><em>&nbsp;</em></p><p><u>Neuroleptic Malignant Syndrome (NMS)</u></p><p>NMS is a potentially life-threatening condition associated with antipsychotic medicinal products. Rare cases reported as NMS have also been received in association with olanzapine. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotic medicines, including olanzapine must be discontinued.</p><p>&nbsp;</p><p><u>Hyperglycaemia and diabetes</u></p><p>Hyperglycaemia and/or development or exacerbation of diabetes occasionally associated with ketoacidosis or coma has been reported uncommonly , including some fatal cases (see section 4.8). In some cases, a prior increase in body weight has been reported which may be a predisposing factor. Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines, e.g. measuring of blood glucose at baseline, 12 weeks after starting olanzapine treatment and annually thereafter.&nbsp; Patients treated with any antipsychotic medicines, including ZYPREXA, should be observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia, and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus should be monitored regularly for worsening of glucose control. Weight should be monitored regularly, e.g. at baseline, 4, 8 and 12 weeks after starting olanzapine treatment and quarterly thereafter.</p><p>&nbsp;</p><p><u>Lipid alterations</u></p><p>Undesirable alterations in lipids have been observed in olanzapine-treated patients in placebo-controlled clinical trials (see section 4.8). Lipid alterations should be managed as clinically appropriate, particularly in dyslipidemic patients and in patients with risk factors for the development of lipids disorders. Patients treated with any antipsychotic medicines, including ZYPREXA, should be monitored regularly for lipids in accordance with utilised antipsychotic guidelines, e.g. at baseline, 12 weeks after starting olanzapine treatment and every 5 years thereafter.</p><p>&nbsp;</p><p><u>Anticholinergic activity</u></p><p>While olanzapine demonstrated anticholinergic activity <em>in vitro</em>, experience during the clinical trials revealed a low incidence of related events. However, as clinical experience with olanzapine in patients with concomitant illness is limited, caution is advised when prescribing for patients with prostatic hypertrophy, or paralytic ileus and related conditions.</p><p>&nbsp;</p><p><u>Hepatic function</u></p><p>Transient, asymptomatic elevations of hepatic aminotransferases, ALT, AST have been seen commonly, especially in early treatment. Caution should be exercised and follow-up organised in patients with elevated ALT and/or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines. In cases where hepatitis (including hepatocellular, cholestatic or mixed liver injury) has been diagnosed, olanzapine treatment should be discontinued.</p><p>&nbsp;</p><p><u>Neutropenia</u></p><p>Caution should be exercised in patients with low leukocyte and/or neutrophil counts for any reason, in patients receiving medicines known to cause neutropenia, in patients with a history of drug-induced bone marrow depression/toxicity, in patients with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with myeloproliferative disease. Neutropenia has been reported commonly when olanzapine and valproate are used concomitantly (see section 4.8).</p><p>&nbsp;</p><p><u>Discontinuation of treatment</u></p><p>Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (&ge; 0.01% and &lt; 0.1%) when olanzapine is stopped abruptly.</p><p>&nbsp;</p><p><u>QT interval</u></p><p>In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] &ge;&nbsp;500 milliseconds [msec] at any time post baseline in patients with baseline QTcF &lt;&nbsp;500&nbsp;msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo. However, caution should be exercised when olanzapine is prescribed with medicines known to increase QTc interval, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia.</p><p>&nbsp;</p><p><u>Thromboembolism</u></p><p>Temporal association of olanzapine treatment and venous thromboembolism has been reported uncommonly (&ge; 0.1% and &lt; 1%). A causal relationship between the occurrence of venous thromboembolism and treatment with olanzapine has not been established. However, since patients with schizophrenia often present with acquired risk factors for venous thromboembolism all possible risk factors of VTE e.g. immobilisation of patients, should be identified and preventive measures undertaken.</p><p>&nbsp;</p><p><u>General CNS activity</u></p><p>Given the primary CNS effects of olanzapine, caution should be used when it is taken in combination with other centrally acting medicines and alcohol. As it exhibits <em>in vitro</em> dopamine antagonism, olanzapine may antagonize the effects of direct and indirect dopamine agonists.</p><p>&nbsp;</p><p><u>Seizures</u></p><p>Olanzapine should be used cautiously in patients who have a history of seizures or are subject to factors which may lower the seizure threshold. Seizures have been reported to occur uncommonly in patients when treated with olanzapine. In most of these cases, a history of seizures or risk factors for seizures were reported.</p><p>&nbsp;</p><p><u>Tardive Dyskinesia</u></p><p>In comparator studies of one year or less duration, olanzapine was associated with a statistically significant lower incidence of treatment emergent dyskinesia. However the risk of tardive dyskinesia increases with long term exposure, and therefore if signs or symptoms of tardive dyskinesia appear in a patient on olanzapine, a dose reduction or discontinuation should be considered. These symptoms can temporally deteriorate or even arise after discontinuation of treatment.</p><p>&nbsp;</p><p><u>Postural hypotension</u></p><p>Postural hypotension was infrequently observed in the elderly in olanzapine clinical trials. It is recommended that blood pressure is measured periodically in patients over 65 years.</p><p>&nbsp;</p><p><u>Sudden cardiac death </u></p><p>In postmarketing reports with olanzapine, the event of sudden cardiac death has been reported in patients with olanzapine. In a retrospective observational cohort study, the risk of presumed sudden cardiac death in patients treated with olanzapine was approximately twice the risk in patients not using antipsychotics. In the study, the risk of olanzapine was comparable to the risk of atypical antipsychotics included in a pooled analysis.</p><p><u>Hyperprolactinemia</u></p><p>As with other drugs that antagonize dopamine D receptors, olanzapine elevates prolactin levels, and the elevation persists during chronic administration. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported in patients receiving prolactinelevating compounds. Long-standing hyperprolactinemia when associated with hypogonadism may lead to decreased bone density in both female and male subjects.</p><p>Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent in vitro, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. As is common with compounds which increase prolactin release, an increase in mammary gland neoplasia was observed in the olanzapine carcinogenicity studies conducted in mice and rats. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time.</p><p>In placebo-controlled olanzapine clinical studies (up to 12 weeks), changes from normal to high in prolactin concentrations were observed in 30% of adults treated with olanzapine as compared to 10.5% of adults treated with placebo. In a pooled analysis from clinical studies including 8136 adults treated with olanzapine, potentially associated clinical manifestations included menstrual-related events<sup>1</sup> (2% [49/3240] of females), sexual function-related events<sup>2</sup> (2% [150/8136] of females and males), and breastrelated events<sup>3</sup> (0.7% [23/3240] of females, 0.2% [9/4896] of males).</p><p>In placebo-controlled olanzapine monotherapy studies in adolescent patients (up to 6 weeks) with schizophrenia or bipolar I disorder (manic or mixed episodes), changes from normal to high in prolactin concentrations were observed in 47% of olanzapinetreated patients compared to 7% of placebo-treated patients. In a pooled analysis from clinical trials including 454 adolescents treated with olanzapine, potentially associated clinical manifestations included menstrual-related events<sup>1</sup> (1% [2/168] of females), sexual function-related events<sup>2</sup> (0.7% [3/454] of females and males), and breast-related events<sup>3</sup> (2% [3/168] of females, 2% [7/286] of males).</p><p><sup>1</sup>Based on a search of the following terms: amenorrhea, hypomenorrhea, menstruation delayed, and oligomenorrhea.</p><p><sup>2</sup>Based on a search of the following terms: anorgasmia, delayed ejaculation, erectile dysfunction, decreased libido, loss of libido, abnormal orgasm, and sexual dysfunction.</p><p><sup>3</sup>Based on a search of the following terms: breast discharge, enlargement or swelling, galactorrhea, gynecomastia, and lactation disorder.</p><p>Dose group differences with respect to prolactin elevation have been observed. In asingle 8-week randomized, double-blind, fixed-dose study comparing 10 (N=199), 20 (N=200) and 40 (N=200) mg/day of oral olanzapine in adult patients with schizophrenia or schizoaffective disorder, incidence of prolactin elevation &gt;24.2 ng/mL (female) or &gt;18.77 ng/mL (male) at any time during the trial (10 mg/day: 31.2%; 20 mg/day: 42.7%; 40 mg/day: 61.1%) indicated significant differences between 10 vs 40 mg/day and 20 vs 40 mg/day.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;Olanzapine is not indicated for use in the treatment of children and adolescents. Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels(see sections 4.8 and 5.1).</p><p>&nbsp;</p><p><u>Lactose</u></p><p>Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose‑galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interaction studies have only been performed in adults.</p><p><u>Potential interactions affecting olanzapine</u></p><p>Since olanzapine is metabolised by CYP1A2, substances that can specifically induce or inhibit this isoenzyme may affect the pharmacokinetics of olanzapine.</p><p><u>Induction of CYP1A2</u></p><p>The metabolism of olanzapine may be induced by smoking and carbamazepine, which may lead to reduced olanzapine concentrations. Only slight to moderate increase in olanzapine clearance has been observed. The clinical consequences are likely to be limited, but clinical monitoring is recommended and an increase of olanzapine dose may be considered if necessary (see section 4.2).</p><p><u>Inhibition of CYP1A2</u></p><p>Fluvoxamine, a specific CYP1A2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine. The mean increase in olanzapine C<sub>max</sub> following fluvoxamine was 54 % in female non-smokers and 77 % in male smokers. The mean increase in olanzapine AUC was 52 % and 108&nbsp;% respectively. A lower starting dose of olanzapine should be considered in patients who are using fluvoxamine or any other CYP1A2 inhibitors, such as ciprofloxacin. A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP1A2 is initiated.</p><p><u>Decreased bioavailability</u></p><p>Activated charcoal reduces the bioavailability of oral<strong> </strong>olanzapine by 50 to 60% and should be taken at least 2 hours before or after olanzapine.</p><p>Fluoxetine (a CYP2D6 inhibitor), single doses of antacid (aluminium, magnesium) or cimetidine have not been found to significantly affect the pharmacokinetics of olanzapine.</p><p><u>Potential for olanzapine to affect other medicinal products</u></p><p>Olanzapine may antagonise the effects of direct and indirect dopamine agonists.</p><p>Olanzapine does not inhibit the main CYP450 isoenzymes <em>in vitro</em> (e.g. 1A2, 2D6, 2C9, 2C19, 3A4). Thus no particular interaction is expected as verified through <em>in vivo</em> studies where no inhibition of metabolism of the following active substances was found: tricyclic antidepressant (representing mostly CYP2D6 pathway), warfarin (CYP2C9), theophylline (CYP1A2) or diazepam (CYP3A4 and 2C19).</p><p>Olanzapine showed no interaction when co-administered with lithium or biperiden.</p><p>Therapeutic monitoring of valproate plasma levels did not indicate that valproate dosage adjustment is required after the introduction of concomitant olanzapine.</p><p><u>General CNS activity</u></p><p>Caution should be exercised in patients who consume alcohol or receive medicinal products that can cause central nervous system depression.</p><p>The concomitant use of olanzapine with anti-Parkinsonian medicinal products in patients with Parkinson&#39;s disease and dementia is not recommended (see section 4.4).</p><p><u>QTc interval</u></p><p>Caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase QTc interval (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no adequate and well-controlled studies in pregnant women. Patients should be advised to notify their physician if they become pregnant or intend to become pregnant during treatment with olanzapine. Nevertheless, because human experience is limited, olanzapine should be used in pregnancy only if the potential benefit justifies the potential risk to the foetus.</p><p>&nbsp;</p><p>New born infants exposed to antipsychotics (including olanzapine) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder. Consequently, newborns should be monitored carefully.</p><p>&nbsp;</p><p><u>Lactation</u></p><p>In a study in breast-feeding, healthy women, olanzapine was excreted in breast milk. Mean infant exposure (mg/kg) at steady state was estimated to be 1.8% of the maternal olanzapine dose (mg/kg). Patients should be advised not to breast feed an infant if they are taking olanzapine.</p><p>Olanzapine is present in human milk. There are reports of excess sedation, irritability, poor feeding and extrapyramidal symptoms (tremors and abnormal muscle movements) in infants exposed to olanzapine through breast milk (see Clinical. There is no information on the effects of olanzapine on milk production.</p><p>The developmental and health benefits of breastfeeding should be considered along with the mother&rsquo;s clinical need for olanzapine and any potential adverse effects on the breastfed child from olanzapine or from the mother&rsquo;s underlying condition.</p><p>Infants exposed to olanzapine should be monitored for excess sedation, irritability, poor feeding, and extrapyramidal symptoms (tremors and abnormal muscle movements).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Fertility</u></p><p><strong><u>Infertility</u></strong></p><p>Females</p><p>Based on the pharmacologic action of olanzapine (D receptor antagonism), treatment with olanzapine may result in an increase in serum prolactin levels, which may lead to a reversible reduction in fertility in females of reproductive potential [see section 4.4].</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Because olanzapine may cause somnolence and dizziness, patients should be cautioned about operating machinery, including motor vehicles.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p><em>Adults</em></p><p>The most frequently&nbsp; (seen in &ge;&nbsp;1% of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>The following table lists the adverse reactions&nbsp; and laboratory investigations observed from spontaneous reporting and in clinical trials. Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. The frequency terms listed are defined as follows: Very common (&ge; 1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000), very rare (&lt;&nbsp;1/10,000), not known (cannot be estimated from the data available).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Very common</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Blood and the lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Eosinophilia</p><p>Leukopenia<sup>10</sup> Neutropenia<sup>10</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopenia<sup>11</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity<sup>11</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Weight gain<sup>1</sup></p></td><td colspan="2" style="vertical-align:top"><p>Elevated cholesterol levels<sup>2,3</sup></p><p>Elevated glucose levels<sup>4</sup></p><p>Elevated triglyceride levels<sup>2,5</sup></p><p>Glucosuria</p><p>Increased appetite</p></td><td style="vertical-align:top"><p>Development or exacerbation of diabetes occasionally associated with ketoacidosis or coma, including some fatal cases (see section 4.4)<sup> 11</sup></p></td><td style="vertical-align:top"><p>Hypothermia<sup>12</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Somnolence</p></td><td colspan="2" style="vertical-align:top"><p>Dizziness</p><p>Akathisia<sup>6</sup></p><p>Parkinsonism<sup>6 </sup>Dyskinesia<sup>6</sup></p></td><td style="vertical-align:top"><p>Seizures where in most cases a history of seizures or risk factors for seizures were reported <sup>11</sup></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Dystonia (including oculogyration)<sup>11</sup></p><p>Tardive dyskinesia<sup>11</sup></p><p>&nbsp;</p><p>Amnesia <sup>9</sup></p><p><sup>&nbsp;</sup></p><p>Dysarthria</p><p>Stuttering<sup>11</sup></p><p>Restless Legs Syndrome<sup>11</sup></p></td><td style="vertical-align:top"><p>Neuroleptic malignant syndrome (see section 4.4) <sup>12</sup></p><p>Discontinuation symptoms<sup>7,</sup><sup>12</sup></p></td><td style="vertical-align:top"><p>Somnambulism</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bradycardia</p><p>QT<sub>c </sub>prolongation (see section 4.4)</p></td><td style="vertical-align:top"><p>Ventricular tachycardia/fibrillation, sudden death (see section 4.4)<sup>11</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Orthostatic hypotension<sup>10</sup></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thromboembolism (including pulmonary embolism and deep vein thrombosis) (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Epistaxis<sup>9</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Mild, transient anticholinergic effects including constipation and dry mouth</p></td><td style="vertical-align:top"><p>Abdominal distension<sup>9</sup></p><p>Salivary</p><p>hypersecretion<sup>11</sup></p></td><td style="vertical-align:top"><p>Pancreatitis<sup>11</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Transient, asymptomatic elevations of hepatic aminotransferases (ALT, AST), especially in early treatment (see section 4.4)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatitis (including hepatocellular, cholestatic or mixed liver injury)<sup>11</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Photosensitivity reaction</p><p>Alopecia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p>Arthralgia<sup>9</sup></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Rhabdomyolysis<sup>11</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urinary incontinence, urinary retention</p><p>Urinary hesitation<sup>11</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Pregnancy, puerperium and perinatal conditions&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Drug withdrawal syndrome neonatal (see section 4.6)</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Reproductive system and breast disorders</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Erectile dysfunction in males</p><p>Decreased libido in males and females</p></td><td style="vertical-align:top"><p>Amenorrhea</p><p>Breast enlargement</p><p>Galactorrhea in females Gynaecomastia/breast enlargement in males</p></td><td style="vertical-align:top"><p>Priapism<sup>12</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Asthenia</p><p>Fatigue</p><p>Oedema</p><p>Pyrexia<sup>10</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Elevated plasma prolactin levels<sup>8</sup></p></td><td colspan="2" style="vertical-align:top"><p>Increased alkaline phosphatase<sup>10</sup></p><p>High creatine phosphokinase<sup>11</sup></p><p>High Gamma</p><p>Glutamyltransferase <sup>10</sup></p><p>High uric acid <sup>10</sup></p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased total bilirubin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="7" style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Inappropriate antidiuretic hormone secretion</p></td></tr></tbody></table><p><sup>1</sup>&nbsp;Clinically significant weight gain was observed across all baseline Body Mass Index (BMI) categories. Following short term treatment (median duration 47 days), weight gain &ge;&nbsp;7% of baseline body weight&nbsp; was very common (22.2 %), &ge;15 % was common (4.2 &nbsp;%) and &ge; &nbsp;25 &nbsp;% was uncommon (0.8 &nbsp;%). Patients gaining &ge; &nbsp;7 &nbsp;%, &nbsp;&ge; &nbsp;15 &nbsp;% and &ge; &nbsp;25 &nbsp;% of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4 &nbsp;%, 31.7 &nbsp;% and 12.3 &nbsp;% respectively).</p><p>&nbsp;</p><p><sup>2</sup> Mean increases in fasting lipid values (total cholesterol, LDL cholesterol, and triglycerides) were greater in patients without evidence of lipid dysregulation at baseline.</p><p>&nbsp;</p><p><sup>3</sup> Observed for fasting normal levels at baseline (&lt;&nbsp;5.17&nbsp;mmol/l) which increased to high (&ge;&nbsp;6.2&nbsp;mmol/l). Changes in total fasting cholesterol levels from borderline at baseline (&ge;&nbsp;5.17 - &lt;&nbsp;6.2&nbsp;mmol/l) to high (&ge;&nbsp;6.2&nbsp;mmol/l) were very common.</p><p>&nbsp;</p><p><sup>4 </sup>Observed for fasting normal levels at baseline (&lt;&nbsp;5.56&nbsp;mmol/l) which increased to high (&ge;&nbsp;7&nbsp;mmol/l). Changes in fasting glucose from borderline at baseline (&ge;&nbsp;5.56 - &lt;&nbsp;7&nbsp;mmol/l) to high (&ge;&nbsp;7&nbsp;mmol/l) were very common.</p><p>&nbsp;</p><p><sup>5 </sup>Observed for fasting normal levels at baseline (&lt;&nbsp;1.69&nbsp;mmol/l) which increased to high (&ge;&nbsp;2.26&nbsp;mmol/l). Changes in fasting triglycerides from borderline at baseline (&ge;&nbsp;1.69&nbsp;mmol/l - &lt;&nbsp;2.26&nbsp;mmol/l) to high (&ge;&nbsp;2.26&nbsp;mmol/l) were very common.</p><p>&nbsp;</p><p><sup>6 </sup>In clinical trials, the incidence of Parkinsonism and dystonia in olanzapine-treated patients was numerically higher, but not statistically significantly different from placebo. Olanzapine-treated patients had a lower incidence of Parkinsonism, akathisia and dystonia compared with titrated doses of haloperidol. In the absence of detailed information on the pre-existing history of individual acute and tardive extrapyramidal movement disorders, it cannot be concluded at present that olanzapine produces less tardive dyskinesia and/or other tardive extrapyramidal syndromes.</p><p>&nbsp;</p><p><sup>7</sup> Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea and vomiting have been reported when olanzapine is stopped abruptly.</p><p>&nbsp;</p><p><sup>8</sup> In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of normal range in approximately 30 % of olanzapine treated patients with normal baseline prolactin value. In the majority of these patients the elevations were generally mild, and remained below two times the upper limit of normal range.</p><p>&nbsp;</p><p><sup>9</sup> Adverse event identified from clinical trials in the Olanzapine Integrated Database.</p><p>&nbsp;</p><p><sup>10</sup> As assessed by measured values from clinical trials in the Olanzapine Integrated Database.</p><p>&nbsp;</p><p><sup>11</sup> Adverse event identified from spontaneous post-marketing reporting with frequency determined utilising the Olanzapine Integrated Database.</p><p>&nbsp;</p><p><sup>12</sup> Adverse event identified from spontaneous post-marketing reporting with frequency estimated at the upper limit of the 95% confidence interval utilising the Olanzapine Integrated Database.</p><p><em><u>&nbsp;</u></em></p><p><u>Long-term exposure (at least 48 &nbsp;weeks)</u></p><p>The proportion of patients who had adverse, clinically significant changes in weight gain, glucose, total/LDL/HDL cholesterol or triglycerides increased over time. In adult patients who completed 9-12 months of therapy, the rate of increase in mean blood glucose slowed after approximately 6 months.</p><p><em><u>&nbsp;</u></em></p><p><u>Additional information on special populations</u></p><p>In clinical trials in elderly patients with dementia, olanzapine treatment was associated with a higher incidence of death and cerebrovascular adverse reactions compared to placebo (see section 4.4). Very common adverse reactions associated with the use of olanzapine in this patient group were abnormal gait and falls. Pneumonia, increased body temperature, lethargy, erythema, visual hallucinations and urinary incontinence were observed commonly.</p><p>&nbsp;</p><p>In clinical trials in patients with drug-induced (dopamine agonist) psychosis associated with Parkinson&rsquo;s disease, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo.</p><p>&nbsp;</p><p>In one clinical trial in patients with bipolar mania, valproate combination therapy with olanzapine resulted in an incidence of neutropenia of 4.1 %; a potential contributing factor could be high plasma valproate levels. Olanzapine administered with lithium or valproate resulted in increased levels (&sup3;&nbsp; 10 %) of tremor, dry mouth, increased appetite, and weight gain. Speech disorder was also reported commonly. During treatment with olanzapine in combination with lithium or divalproex, an increase of &nbsp;&sup3;<u>&nbsp;</u>7 % from baseline body weight occurred in 17.4 % of patients during acute treatment (up to 6 weeks). Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of &sup3;&nbsp;7 % from baseline body weight in 39.9 % of patients.</p><p>&nbsp;</p><p>Olanzapine administered with lithium or valproate was associated with increased levels (olanzapine combination vs. placebo) of tremor (23% vs 13%), dry mouth (32% vs 9%), increased appetite (24% vs 8<strong>%), increased salivation</strong> (6% vs 2%) , weight gain(26% vs 7%), dizziness (14% vs 7%), back pain (8% vs 4%), constipation (8% vs 4%). Speech disorder&nbsp; (7% vs 1%) was also reported commonly, amnesia (5% vs 2%), and paresthesia (5% vs 2%).</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p>Olanzapine is not indicated for the treatment of children and adolescent patients below 18 years. Although no clinical studies designed to compare adolescents to adults have been conducted, data from the adolescent trials were compared to those of the adult trials.</p><p><u>&nbsp;</u></p><p>The following table summarises the adverse reactions reported with a greater frequency in adolescent patients (aged 13-17 years) than in adult patients or adverse reactions only identified during short-term<u> </u>clinical trials in adolescent patients. Clinically significant weight gain (&ge;&nbsp;7 %) appears to occur more frequently in the adolescent population compared to adults with comparable exposures. The magnitude of weight gain and the proportion of adolescent patients who had clinically significant weight gain were greater with long-term exposure (at least 24 weeks) than with short-term exposure.</p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. The frequency terms listed are defined as follows: Very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p><p><em>Very common:</em> Weight gain<sup>13</sup>, elevated triglyceride levels<sup>14</sup>, increased appetite.</p><p><em>Common:<strong> </strong></em>Elevated cholesterol levels<sup>15</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p><p><em>Very common:</em> Sedation (including: hypersomnia, lethargy, somnolence).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p><p><em>Common:</em> Dry mouth</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p><p><em>Very common:</em> Elevations of hepatic aminotransferases (ALT/AST; see section 4.4).</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations </strong></p><p><em>Very common:</em> Decreased total bilirubin, increased GGT, elevated plasma prolactin levels<sup>16</sup>.</p></td></tr></tbody></table><p>&nbsp;</p><p><sup>13</sup> Following short term treatment (median duration 22 days), weight gain &ge;&nbsp;7 &nbsp;% of baseline body weight (kg) was very common (40.6 &nbsp;%), &ge;&nbsp;15 &nbsp;% of baseline body weight was common (7.1 &nbsp;%) and &ge; 25 &nbsp;% was common (2.5%). With long-term exposure (at least 24 weeks), 89.4 &nbsp;% gained &ge; 7 &nbsp;%, 55.3 &nbsp;% gained &ge; 15 &nbsp;% and 29.1 &nbsp;% gained &ge; 25 &nbsp;% of their baseline body weight.</p><p>&nbsp;</p><p><sup>14&nbsp; </sup>Observed for fasting normal levels at baseline (&lt;&nbsp;1.016&nbsp;mmol/l) which increased to high (&ge;&nbsp;1.467&nbsp;mmol/l) and changes in fasting triglycerides from borderline at baseline (&ge;&nbsp;1.016&nbsp;mmol/l - &lt;&nbsp;1.467&nbsp;mmol/l) to high (&ge;&nbsp;1.467&nbsp;mmol/l).</p><p>&nbsp;</p><p><sup>15</sup><sup> </sup>Changes in total fasting cholesterol levels from normal at baseline (&lt;&nbsp;4.39&nbsp;mmol/l) to high (&ge;&nbsp;5.17&nbsp;mmol/l) were observed commonly. Changes in total fasting cholesterol levels from borderline at baseline (&ge;&nbsp;4.39 - &lt;&nbsp;5.17&nbsp;mmol/l) to high (&ge;&nbsp;5.17&nbsp;mmol/l) were very common.</p><p>&nbsp;</p><p><sup>16</sup> Elevated plasma prolactin levels were reported in 47.4 % of adolescent patients.</p><p>&nbsp;</p><p><u>Additional information on special populations:</u></p><p><u>&nbsp;</u></p><p><strong>&nbsp;</strong></p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed below:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Please report adverse drug events to:<br />The National Pharmacovigilance Centre (NPC):<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</strong></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Signs and symptoms</u></p><p>Very common symptoms in overdose (&gt; 10 % incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.</p><p>Other medically significant sequelae of overdose include delirium, convulsion, coma, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension, cardiac arrhythmias (&lt; 2 % of overdose cases) and cardiopulmonary arrest. Fatal outcomes have been reported for acute overdoses as low as 450&nbsp;mg but survival has also been reported following acute overdose of approximately 2&nbsp;g of oral olanzapine.</p><p><u>Management</u></p><p>There is no specific antidote for olanzapine. Induction of emesis is not recommended. Standard procedures for management of overdose may be indicated (i.e. gastric lavage, administration of activated charcoal). The concomitant administration of activated charcoal was shown to reduce the oral bioavailability of olanzapine by 50 to 60 %.</p><p>Symptomatic treatment and monitoring of vital organ function should be instituted according to clinical presentation, including treatment of hypotension and circulatory collapse and support of respiratory function. Do not use epinephrine, dopamine, or other sympathomimetic agents with beta-agonist activity since beta stimulation may worsen hypotension. Cardiovascular monitoring is necessary to detect possible arrhythmias. Close medical supervision and monitoring should continue until the patient recovers.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: psycholeptics, diazepines, oxazepines, thiazepines and oxepines, ATC code N05A H03.</p><p><u>Pharmacodynamic effects</u></p><p>Olanzapine is an antipsychotic, antimanic and mood stabilising agent that demonstrates a broad pharmacologic profile across a number of receptor systems.</p><p>In preclinical studies, olanzapine exhibited a range of receptor affinities (K<sub>i &nbsp;</sub>&lt; 100&nbsp;nM) for serotonin 5 HT<sub>2A/2C</sub>, 5 HT<sub>3</sub>, 5 HT<sub>6</sub>; dopamine D<sub>1</sub>, D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub>, D<sub>5</sub>; cholinergic muscarinic receptors M<sub>1</sub>‑M<sub>5</sub>; a<sub>1</sub> adrenergic; and histamine H<sub>1</sub> receptors. Animal behavioural studies with olanzapine indicated 5HT, dopamine, and cholinergic antagonism, consistent with the receptor-binding profile. Olanzapine demonstrated a greater <em>in vitro</em> affinity for serotonin 5HT<sub>2</sub> than dopamine D<sub>2</sub> receptors and greater 5 HT<sub>2</sub> than D<sub>2</sub> activity <em>in vivo</em> models. Electrophysiological studies demonstrated that olanzapine selectively reduced the firing of mesolimbic (A10) dopaminergic neurons, while having little effect on the striatal (A9) pathways involved in motor function. Olanzapine reduced a conditioned avoidance response, a test indicative of antipsychotic activity, at doses below those producing catalepsy, an effect indicative of motor side-effects. Unlike some other antipsychotic agents, olanzapine increases responding in an &ldquo;anxiolytic&rdquo; test.</p><p>In a single oral dose (10&nbsp;mg) Positron Emission Tomography (PET) study in healthy volunteers, olanzapine produced a higher 5 HT<sub>2A</sub> than dopamine D<sub>2</sub> receptor occupancy. In addition, a Single Photon Emission Computed Tomography (SPECT) imaging study in schizophrenic patients revealed that olanzapine-responsive patients had lower striatal D<sub>2</sub> occupancy than some other antipsychotic- and risperidone-responsive patients, while being comparable to clozapine-responsive patients.</p><p><u>Clinical efficacy</u></p><p>In two of two placebo and two of three comparator controlled trials with over 2,900 schizophrenic patients presenting with both positive and negative symptoms, olanzapine was associated with statistically significantly greater improvements in negative as well as positive symptoms.</p><p>In a multinational, double-blind, comparative study of schizophrenia, schizoaffective, and related disorders which included 1,481 patients with varying degrees of associated depressive symptoms (baseline mean of 16.6 on the Montgomery-Asberg Depression Rating Scale), a prospective secondary analysis of baseline to endpoint mood score change demonstrated a statistically significant improvement (p =&nbsp;0.001) favouring olanzapine (-6.0) versus haloperidol (-3.1).</p><p>In patients with a manic or mixed episode of bipolar disorder, olanzapine demonstrated superior efficacy to placebo and valproate semisodium (divalproex) in reduction of manic symptoms over 3 weeks. Olanzapine also demonstrated comparable efficacy results to haloperidol in terms of the proportion of patients in symptomatic remission from mania and depression at 6 and 12 weeks. In a co-therapy study of patients treated with lithium or valproate for a minimum of 2 weeks, the addition of olanzapine 10&nbsp;mg (co-therapy with lithium or valproate) resulted in a greater reduction in symptoms of mania than lithium or valproate monotherapy after 6 weeks.</p><p>In a 12 month recurrence prevention study in manic episode patients who achieved remission on olanzapine and were then randomised to olanzapine or placebo, olanzapine demonstrated statistically significant superiority over placebo on the primary endpoint of bipolar recurrence. Olanzapine also showed a statistically significant advantage over placebo in terms of preventing either recurrence into mania or recurrence into depression.</p><p>In a second 12 month recurrence prevention study in manic episode patients who achieved remission<u> </u>with a combination of olanzapine and lithium and were then<u> </u>randomised to olanzapine or lithium alone, olanzapine was statistically non-inferior to lithium on the primary endpoint of bipolar recurrence (olanzapine 30.0 %, lithium 38.3 %; p = 0.055).</p><p>In an 18 month co-therapy study in manic or mixed episode patients stabilised with olanzapine plus a mood stabiliser (lithium or valproate), long-term olanzapine co-therapy with lithium or valproate was<s> </s>not statistically significantly superior to lithium or valproate alone in delaying bipolar recurrence, defined according to syndromic (diagnostic) criteria.</p><p><u>Paediatric population</u></p><p>Controlled efficacy data in adolescents (ages 13 to 17 years) are limited to short term studies in schizophrenia (6 weeks) and mania associated with bipolar I disorder (3 weeks), involving less than 200 adolescents.&nbsp; Olanzapine was used as a flexible dose starting with 2.5 and ranging up to 20&nbsp;mg/day. During treatment with olanzapine, adolescents gained significantly more weight compared with adults. The magnitude of changes in fasting total cholesterol, LDL cholesterol, triglycerides, and prolactin (see sections 4.4 and 4.8) were greater in adolescents than in adults.&nbsp; There are no controlled data on maintenance of effect or long term safety (see sections 4.4 and 4.8)<em>.</em> Information on long term safety is primarily limited to open-label, uncontrolled data.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Olanzapine is well absorbed after oral administration, reaching peak plasma concentrations within 5 to 8 hours. The absorption is not affected by food. Absolute oral bioavailability relative to intravenous administration has not been determined.</p><p><u>Distribution</u></p><p>The plasma protein binding of olanzapine was about 93 % over the concentration range of about 7 to about 1000&nbsp;ng/ml. Olanzapine is bound predominantly to albumin and a<sub>1</sub>-acid-glycoprotein.</p><p><u>Biotransformation</u></p><p>Olanzapine is metabolized in the liver by conjugative and oxidative pathways. The major circulating metabolite is the 10-N-glucuronide, which does not pass the blood brain barrier. Cytochromes P450-CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites, both exhibited significantly less <em>in vivo</em> pharmacological activity than olanzapine in animal studies. The predominant pharmacologic activity is from the parent olanzapine.</p><p><u>Elimination</u></p><p>After oral administration, the mean terminal elimination half-life of olanzapine in healthy subjects varied on the basis of age and gender.</p><p>In healthy elderly (65 and over) versus non-elderly subjects, the mean elimination half-life was prolonged (51.8 versus 33.8 hr) and the clearance was reduced (17.5 versus 18.2&nbsp;l/hr). The pharmacokinetic variability observed in the elderly is within the range for the non-elderly. In 44 patients with schizophrenia &gt; &nbsp;65 years of age, dosing from 5 to 20&nbsp;mg/day was not associated with any distinguishing profile of adverse events.</p><p>In female versus male subjects the mean elimination half life was somewhat prolonged (36.7 versus 32.3 hr) and the clearance was reduced (18.9 versus 27.3&nbsp;l/hr). However, olanzapine (5-20&nbsp;mg) demonstrated a comparable safety profile in female (n = 467) as in male patients (n&nbsp; = 869).</p><p><u>Renal impairment</u></p><p>In renally impaired patients (creatinine clearance &lt; 10&nbsp;ml/min) versus healthy subjects, there was no significant difference in mean elimination half-life (37.7 versus 32.4 hr) or clearance (21.2 versus 25.0&nbsp;l/hr). A mass balance study showed that approximately 57 &nbsp;% of radiolabelled olanzapine appeared in urine, principally as metabolites.</p><p><u>Hepatic impairment </u></p><p>A small study of the effect of impaired liver function in 6&nbsp;subjects with clinically significant (Childs Pugh Classification A (n&nbsp;=&nbsp;5) and B (n&nbsp;=&nbsp;1)) cirrhosis revealed little effect on the pharmacokinetics of orally administered olanzapine (2.5&nbsp;&ndash;&nbsp;7.5&nbsp;mg single dose): Subjects with mild to moderate hepatic dysfunction had slightly increased systemic clearance and faster elimination half-time compared to subjects with no hepatic dysfunction (n&nbsp;=&nbsp;3). There were more smokers among subjects with cirrhosis (4/6; 67&nbsp;%) than among subjects with no hepatic dysfunction (0/3; 0&nbsp;%).</p><p><u>Smoking</u></p><p>In non-smoking versus smoking subjects (males and females) the mean elimination half-life was prolonged (38.6 versus 30.4 hr) and the clearance was reduced (18.6 versus 27.7&nbsp;l/hr).</p><p>The plasma clearance of olanzapine is lower in elderly versus young subjects, in females versus males, and in non-smokers versus smokers. However, the magnitude of the impact of age, gender, or smoking on olanzapine clearance and half-life is small in comparison to the overall variability between individuals.</p><p>In a study of Caucasians, Japanese, and Chinese subjects, there were no differences in the pharmacokinetic parameters among the three populations.</p><p><u>Paediatric population</u></p><p>Adolescents (ages 13 to 17 years): The pharmacokinetics of olanzapine are similar between adolescents and adults. In clinical studies, the average olanzapine exposure was approximately 27 % higher in adolescents. Demographic differences between the adolescents and adults include a lower average body weight and fewer adolescents were smokers. Such factors possibly contribute to the higher average exposure observed in adolescents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Acute (single-dose) toxicity</u></p><p>Signs of oral toxicity in rodents were characteristic of potent neuroleptic compounds: hypoactivity, coma, tremors, clonic convulsions, salivation, and depressed weight gain. The median lethal doses were approximately 210&nbsp;mg/kg (mice) and 175&nbsp;mg/kg (rats). Dogs tolerated single oral doses up to 100&nbsp;mg/kg without mortality. Clinical signs included sedation, ataxia, tremors, increased heart rate, labored respiration, miosis, and anorexia. In monkeys, single oral doses up to 100&nbsp;mg/kg resulted in prostration and, at higher doses, semi-consciousness.</p><p><u>Repeated-dose toxicity </u></p><p>In studies up to 3 months duration in mice and up to 1 year in rats and dogs, the predominant effects were CNS depression, anticholinergic effects, and peripheral haematological disorders. Tolerance developed to the CNS depression. Growth parameters were decreased at high doses. Reversible effects consistent with elevated prolactin in rats included decreased weights of ovaries and uterus and morphologic changes in vaginal epithelium and in mammary gland.</p><p><u>Haematologic toxicity</u></p><p>Effects on haematology parameters were found in each species, including dose-related reductions in circulating leukocytes in mice and non-specific reductions of circulating leukocytes in rats; however, no evidence of bone marrow cytotoxicity was found. Reversible neutropenia, thrombocytopenia, or anaemia developed in a few dogs treated with 8 or 10&nbsp;mg/kg/day (total olanzapine exposure [AUC] is 12- to 15-fold greater than that of a man given a 12-mg dose). In cytopenic dogs, there were no adverse effects on progenitor and proliferating cells in the bone marrow.</p><p><u>Reproductive toxicity</u></p><p>Olanzapine had no teratogenic effects. Sedation affected mating performance of male rats. Estrous cycles were affected at doses of 1.1&nbsp;mg/kg (3 times the maximum human dose) and reproduction parameters were influenced in rats given 3&nbsp;mg/kg (9 times the maximum human dose). In the offspring of rats given olanzapine, delays in foetal development and transient decreases in offspring activity levels were seen.</p><p><u>Mutagenicity</u></p><p>Olanzapine was not mutagenic or clastogenic in a full range of standard tests, which included bacterial mutation tests and <em>in vitro</em> and <em>in vivo</em> mammalian tests.</p><p><u>Carcinogenicity</u></p><p>Based on the results of studies in mice and rats, it was concluded that olanzapine is not carcinogenic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p><u>&nbsp;</u></p><p>Lactose monohydrate</p><p>Hyprolose</p><p>Crospovidone</p><p>Microcrystalline cellulose</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Tablet coat</u></p><p><u>&nbsp;</u></p><p><em>ZYPREXA 5&nbsp;mg and 10 mg coated tablets</em></p><p>Hypromellose</p><p>Colour mixture white (hypromellose, titanium dioxide E171, macrogol, polysorbate 80)</p><p>Carnauba wax</p><p>Edible blue ink (shellac, ethanol anhydrous, isopropyl alcohol, butyl alcohol, propylene glycol, ammonium hydroxide, indigo carmine E132)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZYPREXA 5 mg and 10 mg coated tablets
3 years.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from light and moisture. Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cold-formed aluminium blister strips in cartons of 28, 35, 56, 70 or 98 tablets per carton.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing authorization holder:
Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                19 November 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>